As 2023 draws to a close, Bristol Myers Squibb (NYSE: BMY) has announced what is the second biggest pharma M&A deal of the year, and the second acquisition by the US pharma major.
Bristol Myers has entered into a definitive merger agreement to acquire Karuna Therapeutics (Nasdaq: KRTX), a PureTech Health (Nasdaq: PRT) founded company, for $330.00 per share in cash, for a total equity value of $14.0 billion, or $12.7 billion net of estimated cash acquired.
Karuna’s shares leapt 47.3% to $317.00 in pre-market activity following the announcement.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze